title: Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
abstract: Risk of transmission of Creutzfeldt-Jakob disease (infectious agent, responsible of spongiform encephalopathy) via blood and blood components (including the plasma-derived medicinal products such as coagulation factors and immunoglobulins) have been a subject of concern for Health authorities since the early 1980s, with a regain of interest in the 1990s, with the bovine spongiform encephalopathy outbreak followed few years after with the notification of the first cases of variant Creutzfeldt-Jakob disease in humans. The risk-analysis and measures taken by the French authorities in the period 1990-2010 will be described with the various assumptions and working hypothesis used and revisited as new findings become available.
authors.affiliation: French Agency for safety of medicines and health products (ANSM), 143, boulevard Anatole-France, 93285 Saint-Denis, France. Electronic address: marc.martin@ansm.sante.fr.
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: J-H
authors.initials: JH
authors.lastname: Trouvin
mesh_terms: D000818:Animals; D001685:Biological Factors / Q000009:adverse effects; D001798:Blood Proteins / Q000302:isolation & purification; D058731:Blood Safety; D002417:Cattle; D011232:Chemical Precipitation; D007562:Creutzfeldt-Jakob Syndrome / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*; D004196:Disease Outbreaks; D004340:Drug Contamination; D016643:Encephalopathy, Bovine Spongiform / Q000453:epidemiology; D000431:Ethanol; D005374:Filtration; D005602:France / Q000453:epidemiology; D006358:Hot Temperature; D006801:Humans; D011159:Population Surveillance; D011328:Prions / Q000097:blood*; D065227:Transfusion Reaction
chemical_list: D001685:Biological Factors; D001798:Blood Proteins; D011328:Prions; D000431:Ethanol
keywords: Analyse de risque; Creutzfeldt-Jakob disease; Encéphalopathie spongiforme transmissible; Maladie de Creutzfeldt-Jakob; Médicaments dérivés du sang; Plasma-derived medicinal products; Risk analysis; Risque transfusionnel; Transfusion-related risk; Transmissible spongiform encephalopathy